Randomized trial · people
Tirzepatide: HbA1c fell up to 2.07% at 40 weeks in SURPASS-1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In adults with type 2 diabetes, all 3 tirzepatide doses lowered blood sugar and body weight more than placebo over 40 weeks, with mostly gut-related side effects.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 478
- Published
- 2021
- Journal
- Lancet
What they tested
Does tirzepatide taken on its own lower HbA1c (glycated hemoglobin) more than placebo in adults with type 2 diabetes not controlled by diet and exercise alone?
How the study was done
A double-blind, randomized, placebo-controlled phase 3 trial in 478 adults with type 2 diabetes who had never used injectable diabetes drugs, at 52 sites in India, Japan, Mexico and the USA. Participants got once-weekly tirzepatide at 5, 10 or 15 mg, or placebo, for 40 weeks.

Model. Individual results vary.
What they found
HbA1c dropped by 1.87% in the 5 mg arm, 1.89% in the 10 mg arm and 2.07% in the 15 mg arm, while it rose by 0.04% on placebo. An HbA1c below 7.0% was reached by 87-92% of people on tirzepatide versus 20% on placebo, and 31-52% on tirzepatide got below 5.7% versus 1% on placebo. Weight loss grew with dose, ranging from 7.0 to 9.5 kg. The most common side effects were gut problems that were mild to moderate and short-lived, such as nausea (12-18% vs 6%), and no clinically significant or severe low blood sugar was seen on tirzepatide.
What it doesn’t show
The trial lasted 40 weeks and compared tirzepatide alone only with placebo, in adults whose diabetes was not controlled by diet and exercise and who had not used injectable diabetes drugs. It was funded by Eli Lilly and Company.
The paper
Rosenstock et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
The compound
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.